New publication on the PK of ribavirin in Lassa fever published in CID

26. Juli 2022, von Kroemer

High dose ribavirin is an empiric treatment option in Lassa fever disease. Yet, the PK at this dosage and in this patient cohort was not yet characterized so far. Coordinated by the Bernhard-Nocht-Institute for Tropical Medicine in Hamburg, and together with partners in Africa, a PK study on ribavirin in Lassa fever disease was conducted. Our role was to quantify ribavirin in plasma and perform the pharmacometric analysis, both led by Christine Kleist from our team.

Weitere Meldungen

Foto: RG Wicha

16.04.2025|News AG-Wicha

ESCMID Global & ISAP/ EPASG Meeting

This year's congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) took place in Vienna from April 11th to 15th. Our research group was proudly represented by Sebastian, Emily, and Miklas, who showcased their work at both the main congress and the annual...

Foto: RG Wicha

07.03.2025|News AG-Wicha

Pharmacometrics Bootcamp

This week we held our annual Pharmacometrics “Bootcamp” - an introductory course to Pharmacometrics - for the sixth time. For the past five days we heard lectures about various topics in pharmacometric modelling and simulations and worked on hands-on exercises. Topics included an exploratory...